良性前列腺增生治療市場規模、佔有率和成長分析（按治療方法、類型、產品、最終用戶和地區）- 產業預測 2025-2032

2023 年全球良性前列腺增生治療市場規模價值為 114.5 億美元，預計將從 2024 年的 120.8 億美元成長到 2032 年的 185.4 億美元，預測期內（2025-2032 年）的複合年成長率為 5.5%。

由於幾個關鍵因素，良性前列腺增生 (BPH) 治療市場正在經歷顯著成長。人口老化導致全球 BPH 的盛行率上升，尋求治療的患者數量也隨之增加。因此，對創新、微創手術的需求日益增加，例如經尿道前列腺切除術(TURP)、雷射治療和前列腺動脈栓塞術 (PAE)，這些手術具有恢復時間更短、併發症更少等優點。此外，透過公共衛生計劃和教育，人們對 BPH 的認知有所提高，從而提高了對該病症的認知並實現了早期診斷和治療。此外，支持性的法律規範和有利的報銷政策正在推動先進治療方案的採用，進一步促進該領域的市場擴張。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

良性前列腺增生治療市場規模（依治療方法及複合年成長率）（2025-2032）

• 市場概況
• 微創手術
• 侵入性手術

良性前列腺增生治療市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• 藥物治療
  • 阿爾法阻斷劑
  • 阿夫唑嗪
  • 多沙唑嗪
  • Tamsulosin
  • 西洛多辛
  • 其他 α阻斷劑
  • 5-α-還原酶抑制劑
  • Finasteride
  • 度他雄胺
  • 其他藥物類別
• 手術治療
  • 經尿道前列腺切除術(TURP)
  • 尿道熱療法(TUMT)
  • 經尿道攝護腺針刺消融術 (TUNA)
  • 雷射治療
  • 攝護腺支架
  • 泌尿道提升療法
  • Rezam療法
  • 其他手術

良性攝護腺增生治療市場規模（依產品及複合年成長率） (2025-2032)

• 市場概況
• 電切鏡
• 泌尿系統雷射
• 射頻消融術
• 電極
• 導管
• 攝護腺支架
• 植入
• 其他

良性前列腺增生治療市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 家庭醫療保健
• 醫院和診所
• 研究與製造

良性攝護腺增生治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Boston Scientific Corporation（USA）
• Pfizer Inc.（USA）
• GlaxoSmithKline plc（UK）
• Eli Lilly and Company（USA）
• Abbott Laboratories（USA）
• Astellas Pharma Inc.（Japan）
• Sanofi SA（France）
• Merck & Co., Inc.（USA）
• Teleflex Incorporated（USA）
• Olympus Corporation（Japan）
• Coloplast Group（Denmark）
• Asahi Kasei Corporation（Japan）
• Allergan plc（Ireland）
• IPG Photonics Corporation（USA）
• Richard Wolf GmbH（Germany）
• Biolitec AG（Austria）
• Urologix, LLC（USA）
• Procept BioRobotics Corporation（USA）
• Lumenis Ltd.（Israel）
• KARL STORZ SE & Co. KG（Germany）

結論和建議

Global Benign Prostatic Hyperplasia Treatment Market size was valued at USD 11.45 billion in 2023 and is poised to grow from USD 12.08 billion in 2024 to USD 18.54 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The market for Benign Prostatic Hyperplasia (BPH) treatment is experiencing significant growth due to several key factors. The rising global prevalence of BPH, driven by an aging population, is expanding the patient base seeking treatment. Consequently, there is increased demand for innovative, minimally invasive procedures like transurethral resection of the prostate (TURP), laser therapy, and prostatic artery embolization (PAE), which offer benefits such as shorter recovery times and fewer complications. Furthermore, heightened awareness of BPH through public health initiatives and education has improved symptom recognition, leading to earlier diagnoses and treatment. Moreover, supportive regulatory frameworks and favorable reimbursement policies are encouraging the adoption of advanced treatment options, further propelling market expansion in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Benign Prostatic Hyperplasia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Benign Prostatic Hyperplasia Treatment Market Segments Analysis

Global Benign Prostatic Hyperplasia Treatment Market is segmented by Treatment, Type, Product, End User and region. Based on Treatment, the market is segmented into Minimal Invasive Surgery and Invasive Surgery. Based on Type, the market is segmented into Drug Treatment and Surgical Treatment. Based on Product, the market is segmented into Resectoscopes, Urology Laser, Radiofrequency Ablation, Electrodes, Catheters, Prostatic Stents, Implants and Others. Based on End User, the market is segmented into Home Healthcare, Hospitals & Clinics and Research & Manufacturing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Benign Prostatic Hyperplasia Treatment Market

The increasing awareness of benign prostatic hyperplasia (BPH) and its related symptoms is paving the way for earlier detection and diagnosis. Various stakeholders-including governments, healthcare organizations, and advocacy groups-are engaged in efforts to raise awareness through campaigns and screening initiatives focused on BPH. This proactive approach to early intervention and timely treatment not only helps men seek help sooner but also substantially drives the expansion of the BPH treatment market. As awareness grows and initiatives proliferate, a greater number of patients will be likely to pursue available treatment options, thereby enhancing market growth.

Restraints in the Global Benign Prostatic Hyperplasia Treatment Market

The global Benign Prostatic Hyperplasia (BPH) treatment market faces significant restraints due to the expiration of patents on key medications, which has led to an influx of generic versions of treatments like alpha-blockers and 5-alpha reductase inhibitors. This shift has created pricing pressures that negatively impact the revenue streams of branded products. As generic alternatives become more widely available, they offer patients more affordable treatment options, thereby altering market dynamics. Consequently, this heightened competition could hinder the growth potential of branded therapies, making it essential for companies to adapt to the evolving landscape to maintain their market positions.

Market Trends of the Global Benign Prostatic Hyperplasia Treatment Market

The Global Benign Prostatic Hyperplasia (BPH) treatment market is experiencing a marked shift toward minimally invasive procedures, reflecting a broader trend in urological care that prioritizes patient comfort and recovery. Techniques like transurethral resection of the prostate (TURP), laser ablation, and prostatic urethral lift (PUL) are gaining popularity due to their advantages over traditional surgical methods, including reduced hospital stays, quicker recovery times, and fewer postoperative complications. This movement aligns with the growing emphasis on patient-centered care and enhancing the quality of life, as well as the need to optimize healthcare costs, positioning minimally invasive treatments as a driving force in the BPH market's evolution.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Benign Prostatic Hyperplasia Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Minimal Invasive Surgery
• Invasive Surgery

Global Benign Prostatic Hyperplasia Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Drug Treatment
  • Alpha Blockers
  • Alfuzosin
  • Doxazosin
  • Tamsulosin
  • Silodosin
  • Other Alpha Blockers
  • 5-Aplha Reductase Inhibitors
  • Finasteride
  • Dutasteride
  • Other Drug Classes
• Surgical Treatment
  • Transurethral Resection of the Prostate (TURP)
  • Transurethral Microwave Thermotherapy (TUMT)
  • Transurethral Needle Ablation of the Prostate (TUNA)
  • Laser Therapy
  • Prostatic Stenting
  • UroLift Therapy
  • Rezum Therapy
  • Other Surgeries

Global Benign Prostatic Hyperplasia Treatment Market Size by Product & CAGR (2025-2032)

• Market Overview
• Resectoscopes
• Urology Laser
• Radiofrequency Ablation
• Electrodes
• Catheters
• Prostatic Stents
• Implants
• Others

Global Benign Prostatic Hyperplasia Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Home Healthcare
• Hospitals & Clinics
• Research & Manufacturing

Global Benign Prostatic Hyperplasia Treatment Market Size & CAGR (2025-2032)

• North America (Treatment, Type, Product, End User)
  • US
  • Canada
• Europe (Treatment, Type, Product, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Type, Product, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Type, Product, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Type, Product, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olympus Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coloplast Group (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asahi Kasei Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IPG Photonics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Richard Wolf GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biolitec AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Urologix, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Procept BioRobotics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lumenis Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KARL STORZ SE & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations